	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L26	485	semiconduct$3 adj (nanocrystal)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:23			0
2	BRS	L27	792	semiconduct$3 same (nanocrystal)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:24			0
3	BRS	L28	47	ionic adj conjugate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:24			0
4	BRS	L29	76250	linker or (linking adj group)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:25			0
5	BRS	L30	43284	fusion adj protein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:25			0
6	BRS	L31	1	27 same 29 same 30	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:26			0
7	BRS	L32	1	27 same 28	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:26			0
8	BRS	L33	1	(CdSe or ZnS) same (ionic adj conjugate)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:26			0
9	BRS	L34	5815	leucine adj zipper	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:27			0
10	BRS	L35	4119	maltose adj binding adj protein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:27			0
11	BRS	L36	1024	polyaspartate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:27			0
12	BRS	L37	7	immunoglobulin adj g adj binding adj protein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:28			0
13	BRS	L38	1	(34 or 35 or 36 or 37) same 28	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:29			0
14	BRS	L39	1	(34 or 35 or 36 or 37) same 27	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:29			0
15	BRS	L40	343	anderson adj george.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:30			0
16	BRS	L41	1	mattoussi adj hedi.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:30			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
17	BRS	L42	0	mauro adj matthew.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:31			0
18	BRS	L44	45	bawendi adj moungi.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:31			0
19	BRS	L45	13	sundar adj vikram.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:31			0
20	BRS	L46	387	40 or 41 or 42 or 44 or 45	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:32			0
21	BRS	L47	39	46 and (27 or 28)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:33			0
22	BRS	L48	2	46 and (27 or 28) and 29 and 30	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/11/01 18:33			0

=> d his

(FILE 'HOME' ENTERED AT 18:34:43 ON 01 NOV 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
18:35:32 ON 01 NOV 2004
L1 3830 S SEMICONDUCT? (P) NANOCRYSTAL
L2 22 S IONIC CONJUGATE
L3 1851242 S LINK?
L4 167718 S FUSION PROTEIN
L5 2 S L4 (P) L3 (P) L1
L6 1 DUPLICATE REMOVE L5 (1 DUPLICATE REMOVED)
L7 0 S L1 (P) L2
L8 43854 S CDSE OR ZNS
L9 0 S L8 (P) L2
L10 2 S L8 (P) L3 (P) L4
L11 1 DUPLICATE REMOVE L10 (1 DUPLICATE REMOVED)
L12 0 S L11 NOT L6
L13 18890 S LEUCINE ZIPPER
L14 7855 S MALTOSE BINDING PROTEIN
L15 790 S POLYASPARTATE
L16 121 S IMMUNOGLOBULIN G BINDING PROTEIN
L17 27610 S L13 OR L14 OR L15 OR L16
L18 0 S L17 (P) L2
L19 3 S L17 (P) L1
L20 2 DUPLICATE REMOVE L19 (1 DUPLICATE REMOVED)
L21 15057 S ANDERSON G?/AU
L22 160 S MATTOUSSI H?/AU
L23 867 S MAURO M?/AU
L24 356 S BAWENDI M?/AU
L25 164 S SUNDAR V?/AU
L26 16502 S L21 OR L22 OR L23 OR L24 OR L25
L27 1 S L26 AND L2
L28 1 S L27 NOT (L11 OR L20)
L29 115 S L26 AND L1
L30 2 S L29 AND L3 AND L4
L31 1 DUPLICATE REMOVE L30 (1 DUPLICATE REMOVED)
L32 1 S L31 NOT L28

=> log y

```
ILE 'MEDLINE' ENTERED AT 18:35:32 ON 01 NOV 2004

ILE 'CAPLUS' ENTERED AT 18:35:32 ON 01 NOV 2004
SE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
LEASE SEE "HELP USAGETERMS" FOR DETAILS.
OPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

ILE 'BIOSIS' ENTERED AT 18:35:32 ON 01 NOV 2004
opyright (c) 2004 The Thomson Corporation.

ILE 'EMBASE' ENTERED AT 18:35:32 ON 01 NOV 2004
OPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

ILE 'SCISEARCH' ENTERED AT 18:35:32 ON 01 NOV 2004
opyright (c) 2004 The Thomson Corporation.

ILE 'AGRICOLA' ENTERED AT 18:35:32 ON 01 NOV 2004

> s semiconduct? (p) nanocrystal
1        3830 SEMICONDUCT? (P) NANOCRYSTAL

> s ionic conjugate
2          22 IONIC CONJUGATE

> s link?
3     1851242 LINK?

> s fusion protein
4      167718 FUSION PROTEIN

> s l4 (p) l3 (p) l1
5           2 L4 (P) L3 (P) L1

> duplicate remove l5
UPLICATE PREFERENCE IS 'CAPLUS, SCISEARCH'
EEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
ROCESSING COMPLETED FOR L5
6            1 DUPLICATE REMOVE L5 (1 DUPLICATE REMOVED)

> d l6 1 ibib abs

6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN  DUPLICATE 1
CCESSION NUMBER:        2002:91272  CAPLUS
OCUMENT NUMBER:         136:196403
ITLE:                   Luminescent quantum dot-adaptor protein-antibody
                        conjugates for use in fluoroimmunoassays
UTHOR(S):               Goldman, E. R.; Balighian, E. D.; Kuno, M. K.;
                        Labrenz, S.; Tran, P. T.; Anderson, G. P.; Mauro, J.
                        M.; Mattoussi, H.
ORPORATE SOURCE:        Center for Bio/Molecular Science and Engineering, U.S.
                        Naval Research Laboratory, Washington, DC, 20375, USA
OURCE:                  Physica Status Solidi B: Basic Research (2002),
                        229(1), 407-414
                        CODEN: PSSBBD; ISSN: 0370-1972
UBLISHER:               Wiley-VCH Verlag Berlin GmbH
OCUMENT TYPE:           Journal
ANGUAGE:                English
B   A method for the prepn. and characterization of bioinorg. conjugates made
    with highly luminescent   ***semiconductor***   CdSe-ZnS core-shell
    quantum dots (QDs) and antibodies for use in fluoroimmunoassays is
    presented.  The conjugation strategy employs two routes: 1. Use of an
    engineered mol. adaptor protein, attached to the QDs via
    electrostatic/hydrophobic self-assembly, to   ***link***   the inorg.
    fluorophore with antibodies, and 2. use of avidin, also electrostatically
    self-assembled onto the   ***nanocrystal***   surface, which allows QD
    conjugation to biotinylated antibodies via avidin-biotin binding scheme.
    With this approach, the av. no. of antibodies conjugated to a single QD
    can be varied.  In addn., we have developed a simple purifn. strategy
    based on mixed compn. conjugates of the mol. adaptor and a second "inert"
    two-domain   ***fusion***     ***protein***   that allows the use of
    affinity chromatog.  QD/adaptor-antibody conjugates were successfully
    employed in fluoroimmunoassays for the detection of small mol. analytes,
    2,4,6-trinitrobenzene (TNB) and hexahydro-1,3,5-trinitro-1,3,5-triazine
    (RDX).  We also demonstrate the use of QD/avidin-antibody conjugates for
    fluoroimmunoassays using a model protein system.
```

```
LFERENCE COUNT:          14    THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

 d his

    (FILE 'HOME' ENTERED AT 18:34:43 ON 01 NOV 2004)

    FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
    18:35:32 ON 01 NOV 2004
L          3830 S SEMICONDUCT? (P) NANOCRYSTAL
L            22 S IONIC CONJUGATE
L       1851242 S LINK?
L4       167718 S FUSION PROTEIN
L              2 S L4 (P) L3 (P) L1
L5             1 DUPLICATE REMOVE L5 (1 DUPLICATE REMOVED)

 s l1 (p) l2
L            0 L1 (P) L2

 s cdse or zns
L       43854 CDSE OR ZNS

 s l8 (p) l2
L            0 L8 (P) L2

 s l8 (p) L3 (p) l4
L0           2 L8 (P) L3 (P) L4

 duplicate remove l10
UPLICATE PREFERENCE IS 'CAPLUS, SCISEARCH'
EP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
OCESSING COMPLETED FOR L10
L1             1 DUPLICATE REMOVE L10 (1 DUPLICATE REMOVED)

 s l11 not l6
L2           0 L11 NOT L6

 s leucine zipper
L3       18890 LEUCINE ZIPPER

 s maltose binding protein
L4        7855 MALTOSE BINDING PROTEIN

 s polyaspartate
L5         790 POLYASPARTATE

 s immunoglobulin G binding protein
L6         121 IMMUNOGLOBULIN G BINDING PROTEIN

 s l13 or l14 or l15 or l16
L7       27610 L13 OR L14 OR L15 OR L16

 s l17 (p) l2
L8           0 L17 (P) L2

 s l17 (P) l1
L9           3 L17 (P) L1

 duplicate remove l19
UPLICATE PREFERENCE IS 'CAPLUS, SCISEARCH'
EP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
OCESSING COMPLETED FOR L19
L0             2 DUPLICATE REMOVE L19 (1 DUPLICATE REMOVED)

 d l20 1-2 ibib abs

L0  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
CCESSION NUMBER:         2004:810733  CAPLUS
ITLE:                    Self-assembly of phage semiconductor nanowires
UTHOR(S):                Sweeney, Rozamond; Georgiou, George; Iverson, Brent
ORPORATE SOURCE:         Department of Chemistry and Biochemistry, University
                         of Texas at Austin, Austin, TX, 78712, USA
OURCE:                   Abstracts, 60th Southwest Regional Meeting of the
                         American Chemical Society, Fort Worth, TX, United
                         States, September 29-October 4 (2004), SEPT04-398.
                         American Chemical Society: Washington, D. C.
```

CODEN: 69FVXC
OCUMENT TYPE: Conference; Meeting Abstract
B ***Semiconductor*** and metallic nanowires have great potential as nano-electronic circuit components. The organization of nanowires into useful devices remains difficult because of problems in directing self-assembly of individual components. Biol. methods of self-assembling nanowires are being explored because of the high potential for specificity, the diversity of connections, and the ease of manipulation of biol. interactions. Previous work demonstrated that phage could be employed as templates for the synthesis of ***semiconductor*** and metallic nanowires. The next step is to assemble the phage nanowires into useful devices by self-assembly of individual phage. We have exploited ***leucine*** ***zipper*** interactions at the ends of the phage as a means to assemble phage into one- and two-dimensional arrays. We demonstrate the in situ organization of two different sizes of ***semiconductor*** ***nanocrystals*** into alternating linear arrays. Future work includes modifying the phage ends with trimeric ***leucine*** ***zippers*** and modulating the length of individual phage.

20 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
CCESSION NUMBER: 2001:211739 CAPLUS
OCUMENT NUMBER: 134:333943
ITLE: Bioconjugation of highly luminescent colloidal CdSe-ZnS quantum dots with an engineered two-domain recombinant protein
UTHOR(S): Mattoussi, H.; Mauro, J. M.; Goldman, E. R.; Green, T. M.; Anderson, G. P.; Sundar, V. C.; Bawendi, M. G.
ORPORATE SOURCE: Optical Sciences Division, United States Naval Research Laboratory, Washington, DC, 20375, USA
OURCE: Physica Status Solidi B: Basic Research (2001), 224(1), 277-283
CODEN: PSSBBD; ISSN: 0370-1972
UBLISHER: Wiley-VCH Verlag Berlin GmbH
OCUMENT TYPE: Journal
ANGUAGE: English
B The authors present a novel approach, based on mol. self-assembly driven by electrostatic attractions, for conjugating inorg. colloidal ***semiconductor*** ***nanocrystals*** (quantum dots: QDs) having neg. charged surfaces with a 2-domain recombinant protein bearing a pos. charged C-terminal ***leucine*** ***zipper*** domain. Aggregation-free QD/protein conjugate dispersions were prepd. Conjugates retain both properties of the starting materials, i.e., biol. activity of the protein and spectroscopic characteristics of the QDs. Such hybrid bio-inorg. conjugates represent a powerful fluorescent tracking tool, because they combine advantages of CdSe-ZnS quantum dots, such as chem. stability and a wide range of size-dependent luminescence emission properties, with a straightforward electrostatic conjugation approach. The authors describe the design and prepn. of a model QD/protein conjugate and present functional characterization of the conjugate using luminescence and bioassays.
EFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

> d his

(FILE 'HOME' ENTERED AT 18:34:43 ON 01 NOV 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 18:35:32 ON 01 NOV 2004

1	3830	S SEMICONDUCT? (P) NANOCRYSTAL
2	22	S IONIC CONJUGATE
3	1851242	S LINK?
4	167718	S FUSION PROTEIN
5	2	S L4 (P) L3 (P) L1
6	1	DUPLICATE REMOVE L5 (1 DUPLICATE REMOVED)
7	0	S L1 (P) L2
8	43854	S CDSE OR ZNS
9	0	S L8 (P) L2
10	2	S L8 (P) L3 (P) L4
11	1	DUPLICATE REMOVE L10 (1 DUPLICATE REMOVED)
12	0	S L11 NOT L6
13	18890	S LEUCINE ZIPPER
14	7855	S MALTOSE BINDING PROTEIN
15	790	S POLYASPARTATE
16	121	S IMMUNOGLOBULIN G BINDING PROTEIN

```
17       27610 S L13 OR L14 OR L15 OR L16
18           0 S L17 (P) L2
19           3 S L17 (P) L1
20           2 DUPLICATE REMOVE L19 (1 DUPLICATE REMOVED)

> s anderson g?/au
21       15057 ANDERSON G?/AU

> s mattoussi h?/au
22         160 MATTOUSSI H?/AU

> s mauro m?/au
23         867 MAURO M?/AU

> s bawendi m?/au
24         356 BAWENDI M?/AU

> s sundar v?/au
25         164 SUNDAR V?/AU

> s l21 or l22 or l23 or l24 or l25
26       16502 L21 OR L22 OR L23 OR L24 OR L25

> s l26 and l2
27           1 L26 AND L2

> s l27 not (l11 or l20)
28           1 L27 NOT (L11 OR L20)

> d l28 1 ibib abs

28  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
CCESSION NUMBER:         2001:713679  CAPLUS
OCUMENT NUMBER:          135:269662
ITLE:                    Inorganic particle conjugates
NVENTOR(S):                ***Mattoussi, Hedi***  ;   ***Anderson, George P.***
                         ; Mauro, J. Matthew;   ***Bawendi, Moungi G.***  ;
                           ***Sundar, Vikram C.***
ATENT ASSIGNEE(S):       Massachusetts Institute of Technology, USA; Naval
                         Research Laboratory
OURCE:                   PCT Int. Appl., 48 pp.
                         CODEN: PIXXD2
OCUMENT TYPE:            Patent
ANGUAGE:                 English
AMILY ACC. NUM. COUNT:   1
ATENT INFORMATION:

    PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
    ---------------      ----   --------    -------------------      --------
    WO 2001071354         A2    20010927    WO 2001-US8788           20010320
    WO 2001071354         A3    20020801
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
            RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
            VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    US 2002182632         A1    20021205    US 2001-811824           20010320
    EP 1266223            A2    20021218    EP 2001-924209           20010320
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP 2003528321         T2    20030924    JP 2001-569490           20010320
RIORITY APPLN. INFO.:                       US 2000-190766P     P    20000320
                                            WO 2001-US8788      W    20010320
THER SOURCE(S):          MARPAT 135:269662
B   The   ***ionic***     ***conjugates***   include an inorg. particle
    electrostatically assocd. with a macromol. which can interact specifically
    with predetd. chem. species or biol. targets.


> d his

    (FILE 'HOME' ENTERED AT 18:34:43 ON 01 NOV 2004)
```

```
     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     18:35:32 ON 01 NOV 2004
L1          3830 S SEMICONDUCT? (P) NANOCRYSTAL
L2            22 S IONIC CONJUGATE
L3       1851242 S LINK?
L4        167718 S FUSION PROTEIN
L5             2 S L4 (P) L3 (P) L1
L6             1 DUPLICATE REMOVE L5 (1 DUPLICATE REMOVED)
L7             0 S L1 (P) L2
L8         43854 S CDSE OR ZNS
L9             0 S L8 (P) L2
L10            2 S L8 (P) L3 (P) L4
L11            1 DUPLICATE REMOVE L10 (1 DUPLICATE REMOVED)
L12            0 S L11 NOT L6
L13        18890 S LEUCINE ZIPPER
L14         7855 S MALTOSE BINDING PROTEIN
L15          790 S POLYASPARTATE
L16          121 S IMMUNOGLOBULIN G BINDING PROTEIN
L17        27610 S L13 OR L14 OR L15 OR L16
L18            0 S L17 (P) L2
L19            3 S L17 (P) L1
L20            2 DUPLICATE REMOVE L19 (1 DUPLICATE REMOVED)
L21        15057 S ANDERSON G?/AU
L22          160 S MATTOUSSI H?/AU
L23          867 S MAURO M?/AU
L24          356 S BAWENDI M?/AU
L25          164 S SUNDAR V?/AU
L26        16502 S L21 OR L22 OR L23 OR L24 OR L25
L27            1 S L26 AND L2
L28            1 S L27 NOT (L11 OR L20)

=> s l26 and l1
L29          115 L26 AND L1

=> s l29 and l3 and l4
L30            2 L29 AND L3 AND L4

=> s l30 notl28
MISSING OPERATOR L30 NOTL28
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> duplicate remove l30
DUPLICATE PREFERENCE IS 'CAPLUS, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L30
L31            1 DUPLICATE REMOVE L30 (1 DUPLICATE REMOVED)

=> s l31 not l28
L32            1 L31 NOT L28

=> d l32 1 ibib abs

L32  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2002:91272  CAPLUS
DOCUMENT NUMBER:          136:196403
TITLE:                    Luminescent quantum dot-adaptor protein-antibody
                          conjugates for use in fluoroimmunoassays
AUTHOR(S):                Goldman, E. R.; Balighian, E. D.; Kuno, M. K.;
                          Labrenz, S.; Tran, P. T.;   ***Anderson, G. P.***  ;
                          Mauro, J. M.;   ***Mattoussi, H.***
CORPORATE SOURCE:         Center for Bio/Molecular Science and Engineering, U.S.
                          Naval Research Laboratory, Washington, DC, 20375, USA
SOURCE:                   Physica Status Solidi B: Basic Research (2002),
                          229(1), 407-414
                          CODEN: PSSBBD; ISSN: 0370-1972
PUBLISHER:                Wiley-VCH Verlag Berlin GmbH
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   A method for the prepn. and characterization of bioinorg. conjugates made
     with highly luminescent   ***semiconductor***   CdSe-ZnS core-shell
     quantum dots (QDs) and antibodies for use in fluoroimmunoassays is
     presented.  The conjugation strategy employs two routes: 1. Use of an
     engineered mol. adaptor protein, attached to the QDs via
     electrostatic/hydrophobic self-assembly, to   ***link***   the inorg.
     fluorophore with antibodies, and 2. use of avidin, also electrostatically
     self-assembled onto the   ***nanocrystal***   surface, which allows QD
```

conjugation to biotinylated antibodies via avidin-biotin binding scheme. With this approach, the av. no. of antibodies conjugated to a single QD can be varied. In addn., we have developed a simple purifn. strategy based on mixed compn. conjugates of the mol. adaptor and a second "inert" two-domain ***fusion*** ***protein*** that allows the use of affinity chromatog. QD/adaptor-antibody conjugates were successfully employed in fluoroimmunoassays for the detection of small mol. analytes, 2,4,6-trinitrobenzene (TNB) and hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). We also demonstrate the use of QD/avidin-antibody conjugates for fluoroimmunoassays using a model protein system.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 18:34:43 ON 01 NOV 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 18:35:32 ON 01 NOV 2004

```
L1          3830 S SEMICONDUCT? (P) NANOCRYSTAL
L2            22 S IONIC CONJUGATE
L3       1851242 S LINK?
L4        167718 S FUSION PROTEIN
L5             2 S L4 (P) L3 (P) L1
L6             1 DUPLICATE REMOVE L5 (1 DUPLICATE REMOVED)
L7             0 S L1 (P) L2
L8         43854 S CDSE OR ZNS
L9             0 S L8 (P) L2
L10            2 S L8 (P) L3 (P) L4
L11            1 DUPLICATE REMOVE L10 (1 DUPLICATE REMOVED)
L12            0 S L11 NOT L6
L13        18890 S LEUCINE ZIPPER
L14         7855 S MALTOSE BINDING PROTEIN
L15          790 S POLYASPARTATE
L16          121 S IMMUNOGLOBULIN G BINDING PROTEIN
L17        27610 S L13 OR L14 OR L15 OR L16
L18            0 S L17 (P) L2
L19            3 S L17 (P) L1
L20            2 DUPLICATE REMOVE L19 (1 DUPLICATE REMOVED)
L21        15057 S ANDERSON G?/AU
L22          160 S MATTOUSSI H?/AU
L23          867 S MAURO M?/AU
L24          356 S BAWENDI M?/AU
L25          164 S SUNDAR V?/AU
L26        16502 S L21 OR L22 OR L23 OR L24 OR L25
L27            1 S L26 AND L2
L28            1 S L27 NOT (L11 OR L20)
L29          115 S L26 AND L1
L30            2 S L29 AND L3 AND L4
L31            1 DUPLICATE REMOVE L30 (1 DUPLICATE REMOVED)
L32            1 S L31 NOT L28
```

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	71.05	71.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.50	-3.50

STN INTERNATIONAL LOGOFF AT 18:45:10 ON 01 NOV 2004